First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC): 3-year update from CheckMate 9LA

被引：0

作者：

Reinmuth, Niels ^{[1
]}

Paz-Ares, Luis ^{[2
]}

Ciuleanu, Tudor-Eliade ^{[3
,4
]}

Cobo-Dols, Manuel ^{[5
]}

Bennouna, Jaafar ^{[6
,7
]}

Cheng, Ying ^{[8
]}

Mizutani, Hideaki ^{[9
]}

Lingua, Alejo ^{[10
]}

Reyes, Felipe ^{[11
]}

Menezes, Juliana ^{[12
]}

Jassem, Jacek ^{[13
]}

Protsenko, Svetlana ^{[14
]}

Feeney, Kynan ^{[15
]}

De la Mora Jimenez, Emmanuel ^{[16
]}

Lu, Shun ^{[17
]}

John, Thomas ^{[18
]}

Carbone, David Paul ^{[19
]}

Zhang, Xiaoqing ^{[20
]}

Hu, Nan ^{[20
]}

Reck, Martin ^{[21
]}

机构：

[1] Asklepios Lung Clin Munich Gauting, Gauting, Germany

[2] Univ Complutense Madrid, Hosp Univ 12 Octubre, Madrid, Spain

[3] Inst Oncol Prof Dr Ion Chiricuta, Cluj Napoca, Romania

[4] Univ Med & Pharm Iulia Hatieganu, Cluj Napoca, Romania

[5] Hosp Univ Reg & Virgen Victoria, Unidad Gest Clin Interctr Oncol Med, IBIMA, Malaga, Spain

[6] Univ Hosp Nantes, Nantes, France

[7] INSERM, CRCINA, Nantes, France

[8] Jilin Canc Hosp, Changchun, Peoples R China

[9] Saitama Canc Ctr, Saitama, Japan

[10] Inst Med Rio Cuarto SA, Cordoba, Argentina

[11] Fdn Arturo Lopez Perez, Santiago, Chile

[12] Hosp Nossa Senhora Conceicao, Porto Alegre, Brazil

[13] Med Univ Gdansk, Gdansk, Poland

[14] NN Petrov Natl Med Res Ctr Oncol, St Petersburg, Russia

[15] St John God Hosp Murdoch, Perth, WA, Australia

[16] Inst Jalisciense Cancerol, Guadalajara, Mexico

[17] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai Lung Canc Ctr, Shanghai, Peoples R China

[18] Austin Hosp, Heidelberg, Germany

[19] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[20] Bristol Myers Squibb, Princeton, NJ USA

[21] German Ctr Lung Res, Airway Res Ctr North, LungClin, Grosshansdorf, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2022年 / 45卷 / SUPPL 3期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

942

引用

页码：162 / 163

页数：2

共 50 条

[1] First-line Therapy with Nivolumab (NIVO) plus Ipilimumab (IPI)+2 Cycles of Chemotherapy (chemo) vs Chemotherapy alone (4 Cycles) in Patients (pts) with metastatic non-small cell Lung Cancer (mNSCLC): 3-year Update of CheckMate 9LA
Misch, D.
Paz-Ares, L. G.
Ciuleanu, T. -E
Cobo-Dols, M.
Bennouna, J.
Cheng, Y.
Mizutani, H.
Lingua, A.
Reyes, F.
Reinmuth, N.
Menezes, J.
Jassem, J.
Protsenko, S.
Feeney, K.
Jimenez, de la Mora E.
Lu, S.
John, T.
Carbone, D. P.
Zhang, X.
Hu, N.
Reck, M.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 55 - 56
[2] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA.
Paz-Ares, Luis G.
Ciuleanu, Tudor-Eliade
Cobo-Dols, Manuel
Bennouna, Jaafar
Cheng, Ying
Mizutani, Hideaki
Lingua, Alejo
Reyes, Felipe
Reinmuth, Niels
De Menezes, Juliana Janoski
Jassem, Jacek
Protsenko, Svetlana
Feeney, Kynan
Jimenez, Emmanuel De La Mora
Lu, Shun
John, Tom
Carbone, David Paul
Zhang, Xiaoqing
Hu, Nan
Reck, Martin
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (17)
[3] First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): 2-year update from CheckMate 9LA
Reinmuth, N.
Reck, M.
Ciuleanu, T. -E
Cobo, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Juan-Vidal, O.
Alexandru, A.
Sakai, H.
Scherpereel, A.
Lu, S.
Paz-Ares, L.
Carbone, D. P.
Memaj, A.
Marimuthu, S.
Tran, P.
John, T.
ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 53 - 54
[4] First-line (1L) nivolumab (NIVO) plus ipilimumab (IPI) plus chemotherapy (chemo) in Asian patients (pts) with advanced non-small cell lung cancer (NSCLC) from CheckMate 9LA
John, T.
Sakai, H.
Ikeda, S.
Cheng, Y.
Kasahara, K.
Sato, Y.
Nakahara, Y.
Takeda, M.
Kaneda, H.
Zhang, H.
Maemondo, M.
Minato, K.
Hisada, T.
Misumi, Y.
Satouchi, M.
Hotta, K.
Li, A.
Oukessou, A.
Lu, S.
ANNALS OF ONCOLOGY, 2020, 31 : S847 - S848
[5] Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA
John, T.
Ciuleanu, T-E.
Cobo Dols, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E. A.
Bennouna, J.
Cheng, Y.
Felip, E.
Juan Vidal, O. J.
Alexandru, A.
Paz-Ares, L.
Lu, S.
Reck, M.
Hu, N.
Zhang, X.
Grootendorst, D. J.
Eccles, L.
Carbone, D. P.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1034 - S1034
[6] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA
Reck, M.
Ciuleanu, T. -E.
Cobo Dols, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Juan-Vidal, O.
Alexandru, A.
Sakai, H.
Scherpereel, A.
Lu, S.
John, T.
Carbone, D. P.
Meadows-Shropshire, S.
Yan, J.
Paz-Ares, L. G.
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 140 - 140
[7] Nivolumab (NIVO) plus ipilimumab (IPI)+2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA
Reck, M.
Ciuleanu, T. -E.
Dols, M. C.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Vidal, O. J.
Alexandru, A.
Sakai, H.
Scherpereel, A.
Lu, S.
John, T.
Carbone, D. P.
Meadows-Shropshire, S.
Yan, J.
Paz-Ares, L. G.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S2 - S2
[8] First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.
Reck, Martin
Ciuleanu, Tudor-Eliade
Cobo, Manuel
Schenker, Michael
Zurawski, Bogdan
de Menezes, Juliana Janoski
Richardet, Eduardo
Felip, Jaafar Bennouna Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurella
Sakai, Hiroshi
Scherpereel, Arnaud
Lu, Shun
Paz-Ares, Luis G.
Carbone, David Paul
Memaj, Arteid
Marimuthu, Sathiya
Phuong Tran
John, Tom
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[9] First-line nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA
Paz-Ares, L.
Ciuleanu, T-E.
Cobo, M.
Schenker, M.
Zurawski, B.
Menezes, J.
Richardet, E.
Bennouna, J.
Felip, E.
Juan-Vidal, O.
Alexandru, A.
Sakai, H.
Scherpereel, A.
Reck, M.
Lu, S.
John, T.
Meadows-Shropshire, S.
Balli, D.
Agrawal, S.
Carbone, D. P.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S750 - S751
[10] Nivolumab (NIVO) plus ipilimumab (IPI)+2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA.
Reck, Martin
Ciuleanu, Tudor-Eliade
Dols, Manuel Cobo
Schenker, Michael
Zurawski, Bogdan
Menezes, Juliana
Richardet, Eduardo
Bennouna, Jaafar
Felip, Enriqueta
Juan-Vidal, Oscar
Alexandru, Aurella
Sakai, Hiroshi
Scherpereel, Arnaud
Lu, Shun
John, Thomas
Carbone, David Paul
Meadows-Shropshire, Stephanie
Yan, Jinchun
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →